The cell therapy market is exploding with opportunities, and the total market volume for CAR-T therapy alone is expected to reach USD 1 trillion by 2030. China boasts more cell therapy trials than the US, and it is increasingly leveraging its strategic advantage in context to labour costs, precision manufacturing, and now also a more accommodating regulatory regime for this sector.
Part of the 6th Biopharma Development Week, IBCs Cell and Gene Therapy summit will be one of 4 colocated events straddling the entire biopharma value chain. Focusing on investment, regulation, trials and development, the cell therapy market segment will be addressed as a whole, alongside pricing and commercialisation developments.
- 2 Day Conference: CNY 7,000
- Group of 2 or more delegates: CNY 5,000
- Gala Dinner: CNY 350